Αρχική World News EMA Recommends Refusal of the Marketing Authorisation for Tagraxofusp

EMA Recommends Refusal of the Marketing Authorisation for Tagraxofusp

The European Medicines Agency (EMA) has recommended the refusal of the marketing authorisation for tagraxofusp (Elzonris), a medicine intended for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). The Agency issued its opinion on 23 July 2020.

The company that applied for authorisation, Stemline Therapeutics B.V, may ask for re-examination of the opinion within 15 days of receiving the opinion.

Elzonris was developed as a medicine for treating adults with BPDCN, a rare and aggressive type of acute myeloid leukaemia. In BPDCN, the bone marrow produces large numbers of immature white blood cells called plasmacytoid dendritic cells. These build up in the bone marrow, taking the place of normal blood cells, and spread to the skin: most patients develop non-itchy damaged areas, which often look like bruises or nodules. The disease may also cause enlargement of the spleen or liver and a reduction of the number of circulating blood cells.

There is no approved treatment for BPDCN in the EU.

Elzonris contains the active substance tagraxofusp and was to be available as an infusion given into a vein.

Elzonris was designated an orphan medicine (a medicine used in rare diseases) on 11 November 2015 for the treatment of BPDCN.

The active substance in Elzonris, tagraxofusp, is made up of a diphtheria toxin, which has been linked to interleukin-3. The interleukin-3 attaches to receptors, which are found at high levels on the surface of BPDCN cancer cells. Once attached to cancer cells, it is taken up by them, allowing the toxin to be released inside and kill them. This is expected to prevent cancer spread and reduce symptoms of the disease.

To support its application, the company presented results from a single small study involving 47 adults with BPDCN that could not be treated in other ways. The main measure of effectiveness which was recorded in a group of 13 first line patients was the number of patients without any signs of disease after treatment or with just minimal skin damage remaining.

The Agency was concerned that due to the design of the study and the small number of patients involved, it was not possible to be sure how effective the medicine was in treating BPCDN. In addition, the medicine could cause capillary leak syndrome (an unpredictable, potentially life-threatening side effect due to increased permeability of small blood vessels), which had led to some fatal outcomes.

Therefore, the Agency’s opinion was that the benefits of Elzonris did not outweigh its risks and it recommended refusing marketing authorisation.

The company informed the Agency that there are no consequences for patients in clinical trials or in compassionate use programmes with Elzonris.

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

FDA Approves Pembrolizumab Combination for the First-Line Treatment of Cervical Cancer

On 13 October 2021, the US Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) in combination with chemotherapy, with or without bevacizumab, for...

From Scan to Scan: The Challenges of Living with Metastatic Cancer

October 15, 2021, by NCI Staff Bethany Ross has been living with metastatic neuroendocrine cancer since she was diagnosed in 2018. Credit: Used with permission from...

The award-winning researcher behind next generation sequencing

Next generation sequencing (NGS) has given the genomic research community ultra-high throughput, scalability, and speed that could only be dreamed of 20 years ago....

Many Breast Cancer Patients Use Cannabis to Manage Symptoms But Don’t Tell Their Doctors

Cancer and cancer treatment come with many side effects, including nausea, vomiting, and pain. In addition to the physical toll, the impacts to a...

Medicare Open Enrollment Starts Tomorrow!

Medicare open enrollment is upon us for 2022. If you are a Medicare recipient, this is the time of year when you can make...

Cancer in My Community: Providing Supportive Care in Serbia

Cancer in My Community is a Cancer.Net Blog series that shows the global impact of cancer and how people work to care for those with...